The aim was to study the renal and hormonal effects of intravenous 99-126 atrial natriuretic factor (ANF) infusion in a mixed group of patients who had moderate to severe chronic renal failure (CRF) and who were not treated with dialysis. The peak mean plasma level ofANF achieved during the experiment was at the upper limit of an absolute range of basal values previously recorded in a larger group of patients with similar degrees of renal impairment. A significant tissue effect was confirmed by rises in plasma and urinary cyclic guanosine monophosphate, the 'second-messenger' of ANF. ANF infusion increased sodium excretion rate by a mean of 68% compared with a fall of 40% in a placebo group, and significant increases in urinary albumin excretion occurred during the peptide infusion. Thus, the high levels of plasma ANF found in CRF may have a role in the maintenance of sodium balance. In addition, the proteinuric effect may be detrimental to long-term renal function.
Introduction
Sodium balance is maintained in chronic renal failure (CRF) by an increase in fractional excretion of sodium, and it has been suggested that this effect is mediated by an unidentified circulating natriuretic agent.'"2 Recently, atrial natriuretic factor (ANF) has been implicated as an important hormone in the control of plasma volume. In healthy subjects, ANF is released by the heart in response to blood volume expansion,3 and low dose intravenous infusion causes a significant natriuresis.4'5 Cyclic guanosine monophosphate (cGMP) may act as a 'second messenger' to ANF, and extracellular levels of the nucleotide may act as a guide to the tissue action of ANF. 6 Plasma immunoreactive ANF values are often raised in patients with CRF who do not require dialysis,7'8 and this may be due to a combination of volume overload, decreased renal excretion of the peptide together with the frequent occurrence of cardiac disease in this population. However, the biological effects of these high levels are unknown. In order to study the role ofANF in this disorder we have followed the renal and hormonal effects ofintravenous ANF infusion.
Patients and methods
After approval by the Department of Health and the hospitals' ethical committees, 15 patients with stable CRF were recruited from nephrology clinics, and they gave informed consent. None had valvular heart disease, a history of cardiac ischaemia, nephrotic syndrome or peripheral oedema. They were assigned alternately to have either an ANF or placebo infusion. The active group (n = 8, 5 males), had diagnoses of glomerulonephritis (3) , chronic interstitial disease (3), hypertension (1) and adult polycystic disease (1) . The placebo group (n = 7, 3 males) had diagnoses of glomerulonephritis (2) , chronic interstitial disease (4) and hypertension (1) . One patient in each group took their regular nifedipine on the study day, and one subject in each group stopped a thiazide and betablockade two days before the study. Dietary sodium was uncontrolled but the two groups had similar urinary sodium excretion on the day before the experiment (active group, mean ± s.e.m.: 127 ± 23 mmol and placebo group: 145 ± 23 mmol). The daily protein excretion of the active group was 1.27 ± 0.30 g, and of the placebo group was 1.05 0.33g.
On the study day they ate a light breakfast which did not include meat. From 0900-1400 h they sat with legs dependent, rising briefly to pass urine every 30 minutes. Between 0900-0930 h they each drank 1 litre of water, and took 200 ml half-hourly thereafter. At 0900 h, sodium aminohippurate (Merck, Sharp and Dohme) and inulin (Laevosan International) were infused via a forearm vein, to achieve plasma levels of 20 mg/l and 250 mg/l respectively and continued for 5 Basal values in the two groups were similar and are shown in Table I . Significant differences at identical time points are shown in Figure 1 , and significant differences in incremental areas are identified in the text.
During the active infusion the mean plasma ANF rose four-fold, and rapidly returned to basal levels in the recovery hour. Basal plasma cGMP was elevated compared to healthy subjects, and in the active group the mean level increased two-fold. Despite a rise of absolute urinary cGMP excretion from 140 ± 30 to 396 + 87 pmol/min, the fractional excretion of the nucleotide did not change significantly (from 115 ± 19 to 104 + 9%). The incremental areas for plasma ANF, cGMP and urinary cGMP were significantly greater in the active versus the placebo groups (all P <0.01).
Plasma aldosterone tended to fall during the ANF infusion, and then rose in the recovery hour. Plasma aldosterone was constant in the placebo study but the difference between groups was not significant. PRA showed a tendency to fall throughout the study in both groups.
In the active group the mean GFR tended to rise but the individual absolute increments were highly variable, ranging from 2-20 ml/min. However, the difference ofincremental areas ofthe two groups failed to reach significance (P = 0.07). ERPF was constant in both groups.
In the active group urinary sodium increased slowly to reach a peak of 168 ± 20% of basal values in the final half-hour of the ANF infusion, and by the end of the recovery hour had returned to basal values. In this small group, there was no relation between the absolute rise in sodium excretion rate and the initial GFR. Compared to placebos, there was a highly significant increase in incremental area (P <0.001). During the ANF infusion, fractional excretion of sodium tended to rise and then it fell rapidly in the recovery hour to 50% of basal values. In contrast, in the placebo group, there was a steady fall throughout the experiment ofboth absolute and fractional sodium excretion. Urine potassium excretion remained constant in both groups.
In the active group urinary albumin excretion rate increased in all patients to a peak mean of 280 + 110% of basal values during the second hour of the ANF infusion, and then returned to basal values in the group.bmj.com on January 11, 2018 -Published by http://pmj.bmj.com/ Downloaded from Basal data are given as mean ± s.e.m., unless distribution is non-Gaussian, when values are median (range).
recovery hour. The incremental area was significantly greater than in placebos (P = 0.02).
In both groups blood pressure, pulse, plasma electrolytes and plasma albumin were constant. No patient experienced any side effects during either the ANF or placebo infusions.
Discussion
The peak mean plasma value of ANF during the peptide infusion was just above the upper limit of a range of basal levels (1.0-39.0 pmol/l) measured by our laboratory in a larger group of patients with CRF (n = 36) of a similar age and degree of renal impairment.8 This rise of ANF caused a significant tissue effect as judged by the increases of plasma and urinary cGMP.6 At all time periods, in both groups, the ratio of cGMP to inulin clearance was unity and we were unable to detect any nephrogenous nucleotide, confirming previous observations in healthy subjects.'3 Arterial walls are rich in ANF receptors and may contribute the majority of both plasma and urinary cGMP.6 Therefore, urinary cGMP is unlikely to be a marker for the specific renal effects of ANF.
The increase in sodium excretion in the active group contrasted with the fall which occurred in the placebo group. A similar fall has been recorded in another study, and as a group patients with CRF excrete most sodium at night.'4 The ANF-induced natriuresis suggests that the raised levels of plasma peptide found in some patients with CRF7'8 may contribute to sodium balance in this disorder. Although plasma ANF rises in animals with CRF when dietary salt is increased,'5 further studies are required in patients to determine whether the four-fold rise in ANF that we recorded in the active group is compatible with a change caused by dietary sodium loading. When pharmacological doses of ANF are administered to rats with CRF both sodium excretion and GFR are reported to rise.'6 However, we failed to find a major rise in GFR in our patients. Moreover, low-dose ANF administered to healthy subjects produces natriuresis without a significant rise in filtration rate.4'5 Therefore, the importance of a rise in GFR in the ANF-induced natriuresis remains uncertain.
An increase of albuminuria has been recorded after administration of pharmacological doses of ANF to healthy subjects,'7 and during infusion into patients with the nephrotic syndrome. sure and permeability of the glomerular barrier increase,'9 and similar mechanisms could have contributed to the rise in albumin excretion in the studies described above. In patients with chronic glomerulonephritis and pyelonephritis the degree ofproteinuria is a marker for the rate of renal deterioration.20 As well as indicating the severity of glomerular structural and functional changes, the enhanced passage of macromolecules across the glomerulus may cause further structural damage.' In animals with partial renal ablation22 and humans with a variety of primary renal diseases23 the control ofarterial hypertension can reduce proteinuria and stabilize renal function, an effect that may be mediated by the lowering of glomerular capillary pressure in surviving nephrons. 22 In patients with CRF there is a positive correlation between plasma ANF and arterial blood pressure, 7'8 and this may reflect a partial dependence of blood pressure on blood volume.24 It is interesting to speculate that in some patients with CRF, the retention of sodium may lead to both systemic arterial hypertension and a rise of plasma ANF. Both of these changes may then not only serve the homeostatic function of increasing urinary sodium excretion, but could also alter glomerular haemodynamics and increase proteinuria to the detriment of long-term renal function.
